Welcome

CORRECT: Sumitomo, Torrent Settle Patent Suit on Aptiom Drug

Nov. 19, 2021, 4:35 PM

Sumitomo’s Sunovion and closely held Bial-Portela had claimed that Torrent’s proposed generic version of Aptiom infringes patents for the seizure treatment.

  • Sales of Torrent’s copycat are blocked until the 10 patents have expired “except as otherwise provided in the settlement agreement” and “unless pursuant to a license,” according to consent judgment approved Thursday in federal court in Wilmington, Delaware
  • Latest of patents’ expirations is August 2032: FDA Orange Book
    • Patents held by Bial and licensed exclusively to Sunovion
  • Aptiom, trailing only Latuda among Sumitomo’s biggest drugs, had North American sales of $124 million in the first half of ...





To read the full article log in.

Learn more about a Bloomberg Law subscription.